Notably, a previous study (7) reported a trend toward improved overall survival in EGFR-mutant NSCLC patients with concurrent germline BRCA mutations treated with EGFR-TKIs, though this finding was not statistically significant. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.